Pharvaris NV
NASDAQ:PHVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharvaris NV
Total Equity
Pharvaris NV
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
Total Equity
€271.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
See Also
What is Pharvaris NV's Total Equity?
Total Equity
271.3m
EUR
Based on the financial report for Dec 31, 2025, Pharvaris NV's Total Equity amounts to 271.3m EUR.
What is Pharvaris NV's Total Equity growth rate?
Total Equity CAGR 5Y
23%
Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Pharvaris NV have been 22% over the past three years , 23% over the past five years .
